Novotech CRO strengthens South Korean Capabilities with Two Major Hospitals
Novotech, the Asia-Pacific CRO, has further strengthened its presence in South Korea with two major hospitals joining the Novotech partnership program - bringing more investigators, KOLs, and up to 4 million patients.
The 900 bed Ulsan University Hospital (UUH), and the Hepatology Division in Gastroenterology, Department of Internal Medicine at the 1,778 bed Seoul National University Hospital (SNUH), have joined the Novotech CRO partnership program, further strengthening Novotech's clinical service capabilities in South Korea.
South Korea is a growing destination for clinical studies with quality infrastructure, world-class medical and hospital facilities, and supportive rapid start-up regulations. South Korea was Asia's most active country in clinical research after China last year, with over 400 sites opened by biopharma companies.
Novotech is established in Asia with offices in 11 countries and more than 550 staff, while 19 leading hospitals and medical facilities across the region have now joined the Novotech CRO clinical partnership program.
Novotech CEO, Dr. John Moller, said biotech clients were increasingly running Phase I studies in Australia, benefiting from the 41% R&D tax credit, then moving to Asia for subsequent trials. "Having the same company that understands the study as it transitions into Asia is always reassuring for clients. Novotech uses the latest Oracle and Medidata technology, so seamlessly connects with global clinical partners."
For more information go to https://novotech-cro.com/welcome
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
